Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.
January 2023 AbbVie Inc. Company Confidential
Polygenic score-adjusted PSA may improve screening accuracy in prostate cancer
June 2nd 2023“We showed that genetic correction of PSA levels has the potential to both reduce unnecessary biopsies and improve our ability to detect tumors with a more aggressive profile," says Linda Kachuri, PhD, MPH.
2 Clarke Drive
Cranbury, NJ 08512